LM-102

N/A

Report date: 2023/03/10 20:00:33

Base Information

Drug NameLM-102
Drug Alias NameLM-102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLaNova Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesLaNova Medicines Ltd
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms +[4
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A